Glenmark receives USFDA approval for Nitroglycerin Sublingual Tablets

20 Sep 2017 Evaluate

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Nitroglycerin Sublingual Tablets USP, 0.3 mg, 0.4 mg, and 0.6 mg, the generic version of Nitrostat Sublingual Tablets, 0.3 mg, 0.4 mg, and 0.6 mg, of Pfizer, Inc.

According to IMS Health sales data for the 12 month period ending July 2017, the Nitrostat Sublingual Tablets, 0.3 mg, 0.4 mg, and 0.6 mg market achieved annual sales of approximately $112.7 million.

Glenmark’s current portfolio consists of 125 products authorized for distribution in the US marketplace and 61 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.



Glenmark Pharma Share Price

1956.60 3.70 (0.19%)
11-Dec-2025 11:51 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1796.00
Dr. Reddys Lab 1268.20
Cipla 1501.55
Zydus Lifesciences 922.85
Lupin 2073.20
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×